Payment overview · 2025
General Payments
$380.39
22 reported records · 9 companies
Healthcare provider profile · identity verified
Marilyn M Landrum, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DENISON, TX · NPI 1285683987
Verified facts
What the public records show
CMS Open Payments records show Marilyn M Landrum, MD received $380.39 in general payments during 2025 across 22 reported records.
Amgen Inc. accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $105.37 | 27.7% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $66.52 | 17.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.16 | 17.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.40 | 10.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.69 | 8.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.83 | 6.5% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $16.53 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.10 | 4.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.79 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $380.39 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $73.16 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $73.16 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $66.52 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $66.16 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $66.16 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.40 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.69 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.21 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.10 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 92 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
92 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 366 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 313 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 308 | 89 |
| Losartan Potassium | Losartan Potassium | 299 | 81 |
| Gabapentin | Gabapentin | 261 | 75 |
| Montelukast Sodium | Montelukast Sodium | 248 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 72 |
| Simvastatin | Simvastatin | 208 | 65 |
| Lisinopril | Lisinopril | 181 | 52 |
| Trazodone Hcl | Trazodone Hcl | 179 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 45 |
| Omeprazole | Omeprazole | 154 | 50 |
| Sertraline Hcl | Sertraline Hcl | 140 | 39 |
| Ezetimibe | Ezetimibe | 128 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 121 | 40 |
| Furosemide | Furosemide | 114 | 31 |
| Potassium Chloride | Potassium Chloride | 113 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | 31 |
| Meloxicam | Meloxicam | 103 | 30 |
| Metformin Hcl | Metformin Hcl | 101 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 29 |
| Mounjaro | Tirzepatide | 92 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 23 |
| Carvedilol | Carvedilol | 83 | 21 |
| Eliquis | Apixaban | 80 | 21 |
| Alprazolam | Alprazolam | 79 | 36 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 78 | 65 |
| Baclofen | Baclofen | 78 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 24 |
| Tramadol Hcl | Tramadol Hcl | 65 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 20 |
| Estradiol | Estradiol | 59 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 19 |
| Celecoxib | Celecoxib | 55 | 19 |
| Donepezil Hcl | Donepezil Hcl | 55 | 22 |
| Jardiance | Empagliflozin | 53 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 18 |
| Famotidine | Famotidine | 50 | 16 |
| Glimepiride | Glimepiride | 50 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 25 |
| Bupropion Hcl | Bupropion Hcl | 48 | 14 |
| Allopurinol | Allopurinol | 47 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 18 |
| Methocarbamol | Methocarbamol | 46 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 12 |
| Synthroid | Levothyroxine Sodium | 45 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | 14 |
| Alendronate Sodium | Alendronate Sodium | 42 | 15 |
| Fenofibrate | Fenofibrate | 42 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 11 |
| Azithromycin | Azithromycin | 38 | 31 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 33 |
| Ondansetron Odt | Ondansetron | 37 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 28 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | 12 |
| Lovastatin | Lovastatin | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 32 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 25 |
| Spironolactone | Spironolactone | 34 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | 11 |
| Atenolol | Atenolol | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 12 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 17 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Ozempic | Semaglutide | 27 | 11 |
| Pregabalin | Pregabalin | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Finasteride | Finasteride | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 18 |
| Primidone | Primidone | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Linzess | Linaclotide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Humira Pen | Adalimumab | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $380.39 · 22 records | Amgen Inc. | BEYFORTUS, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error